MOMaría Ormaechea

María Ormaechea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Ormaechea has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kidney transplant to vesicostomy: A safe strategy for children with end stage renal disease and lower urinary tract anomalies

    by Pedro Mercado, Roberto Vagni, Francisco de Badiola, María Ormaechea, Cristal Delorenzi, Diego Gallegos, Paula Coccia, Agostina Grillo, Javier Ruiz, Juan Corbetta, et al.


  • [Transitional cell carcinoma of the bladder in adolescents: a diagnosis to bear in mind].

    by Eduardo Ruiz, Martín Alarcón Caba, Luzia Toselli, Juan Moldes, María Ormaechea, Francisco De Badiola, Silvia Christiansen

    Transitional cell carcinoma of the bladder has a high incidence in adults, but it is uncommon in children and adolescents. Hematuria is the most common symptom of presentation and vesical ecography the preferred diagnostic method. The diagnosis and treatment is performed with cystoscopy and endoscopic resection. We describe two patients: an 18 years old male, who presented with a pediculated tumor on the posterior bladder wall and a 15 years old female with a 1 cm long tumor on the posterior wall too; both were removed under endoscopic control. In both patients superficial transitional cell carcinoma was the final diagnosis and are disease free 3 and 5 years later. A review of the available literature was performed to clarify if this type of tumors must be considered malignant and try to define how long and by which way these patients must be controlled.


  • Open Access

    Vantris®, A biocompatible, synthetic, non-biodegradable, easy-to-inject bulking substance: Evaluation of local tissular reaction, localized migration and long-distance migration

    by María Ormaechea, Mario Paladini, Roberto Pisano, Miguel Scagliotti, Rubén Sambuelli, Santiago López, Andrés Guidi, Juan Muñoz, Víctor Rossetti, Manuel Carnerero, et al.

    Biodegradable injectable bulking agents of animal origin present a fast rate of bio-reabsorption and may cause an allergic reaction. Biodegradable elements of synthetic origin have a high rate of reabsorption after a year. Non-biodegradable agents of synthetic origin lead to the formation of a fibrotic capsule, giving stability and long-term permanence. VANTRIS is categorized into this last group; it belongs to the family of Acrylics, particles of polyacrylate polyalcohol copolymer immersed in a glycerol and physiological solution carrier. Molecular mass is very high. When injected in soft tissues, this material causes a bulkiness that remains stable through time. The carrier is a 40% glycerol solution with a pH of 6. Once injected, the carrier is eliminated by the reticular system through the kidneys, without metabolizing. Particles of this polyacrylate polyalcohol with glycerol are highly deformable by compression, and may be injected using a 23-gauge needle. The average of particles size is 320 mm. Once implanted, particles are covered by a fibrotic capsule of up to 70 microns. Particles of this new material are anionic with high superficial electronegativity, thus promoting a low cellular interaction and low fibrotic growth. The new polyacrylate polyalcohol copolymer with glycerol was tested for biocompatibility according to ISO 10993-1:2003 in vitro, showing that they are not mutagenic for the Salmonella T. strains analyzed. The extract turned out to be non-cytotoxic for cell lines in culture and non-genotoxic for mice. In in vivo studies, acrylate did not cause sensitization in mice. The macroscopic reaction of tissue irritation was not significant in subcutaneous implants and in urethras of rabbits. Seven female dogs were injected transurethrally with VANTRIS to evaluate short and long-term migration (13 weeks and 12 months respectively). No particles or signs of inflammation or necrosis are observed in any of the organs examined 13 weeks and 12 months after implantation. To conclude, this new material meets the conditions of ideal tissue bulking material.